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Abstract
Background: A major goal of the analysis of high-dimensional RNA expression data from tumor tissue is to identify 
prognostic signatures for discriminating patient subgroups. For this purpose genome-wide identification of bimodally 
expressed genes from gene array data is relevant because distinguishability of high and low expression groups is easier 
compared to genes with unimodal expression distributions.
Recently, several methods for the identification of genes with bimodal distributions have been introduced. A 
straightforward approach is to cluster the expression values and score the distance between the two distributions. 
Other scores directly measure properties of the distribution. The kurtosis, e.g., measures divergence from a normal 
distribution. An alternative is the outlier-sum statistic that identifies genes with extremely high or low expression values 
in a subset of the samples.
Results: We compare and discuss scores for bimodality for expression data. For the genome-wide identification of 
bimodal genes we apply all scores to expression data from 194 patients with node-negative breast cancer. Further, we 
present the first comprehensive genome-wide evaluation of the prognostic relevance of bimodal genes. We first rank 
genes according to bimodality scores and define two patient subgroups based on expression values. Then we assess 
the prognostic significance of the top ranking bimodal genes by comparing the survival functions of the two patient 
subgroups. We also evaluate the global association between the bimodal shape of expression distributions and 
survival times with an enrichment type analysis.
Various cluster-based methods lead to a significant overrepresentation of prognostic genes. A striking result is 
obtained with the outlier-sum statistic (p < 10-12). Many genes with heavy tails generate subgroups of patients with 
different prognosis.
Conclusions: Genes with high bimodality scores are promising candidates for defining prognostic patient subgroups 
from expression data. We discuss advantages and disadvantages of the different scores for prognostic purposes. The 
outlier-sum statistic may be particularly valuable for the identification of genes to be included in prognostic signatures. 
Among the genes identified as bimodal in the breast cancer data set several have not yet previously been recognized 
to be prognostic and bimodally expressed in breast cancer.
Background
Genome-wide RNA expression analysis with microarrays
has become a standard technology for screening for genes
that are differentially expressed between different entities
of tissues. In the clinical context, a frequent goal is the
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separation of patient groups with respect to prognosis or
therapy outcome. The search for single genes as well as
gene signatures with both prognostic power and corre-
sponding biologically plausible interpretation remains a
major challenge [1-3].
Identifying genes with discriminatory power using
logistic regression type models often yields soft decision
boundaries. However, the ideal situation for personalized
medicine would be a sharp decision boundary, which cor-
responds to a clear separation of the expression values of
a specific gene into two groups. This is particularly rele-
vant for clinical routine, where usually not fresh frozen
but formalin-fixed and paraffin-embedded tumor tissue
is available. Since RNA from paraffin-embedded tissue is
of lower quality than that of fresh frozen tissue the lim-
ited precision of quantitative analysis may add a further
difficulty in classifying patients into low and high expres-
sion groups when genes with unimodal distributions are
applied. In this situation bimodally distributed genes with
a clear distinguishability between patients belonging to a
high and a low expression group would mean an impor-
tant practical advantage.
Bimodal distributions of RNA expression levels in
tumor tissue may be caused by somatic mutations or by
germline polymorphisms. A well-known example of a
somatic or de novo mutation occurring during tumor
development is amplification of the receptor tyrosine
kinase proto-oncogene erbB2 which leads to increased
RNA expression levels [2,4]. On the other hand also sin-
gle nucleotide polymorphisms (SNPs) in the germ line
have been shown to correlate with RNA expression in
tumor tissue and may result in bimodal distribution
curves [5]. Because of the clear distinguishability of high
and low expression groups it could be an advantage to
preferentially include bimodally distributed prognostic
genes in prognostic signatures. In the literature various
methods for the identification of genes with bimodal dis-
tributions have been introduced [6-9]. Several authors
suggest approaches based on clustering the expression
values of a gene into two groups and constructing scores
for bimodality from the clustering result. Ertel and Toz-
eren (2008) [6] use the likelihood ratio of a normal model
with one component and a normal mixture model with
two components fitted to the expression values. The
bimodality index suggested by Wang et al. (2009) [9] is
based on the standardized difference of the cluster
means. In this paper we introduce two further methods
based on the comparison of the within cluster variance
with the total variance.
The bimodality of a gene expression profile can be eval-
uated using the Dip Test of Unimodality suggested by
Hartigan and Hartigan (1985) [7]. Other scores directly
measure properties of the distribution, for example the
kurtosis. In the case of two approximately equally sized
groups the kurtosis is negative, distributions with many
outliers have positive kurtosis. This approach was sug-
gested by Teschendorff et al. (2006) [8].
An interesting alternative are outlier detection methods
that search for genes with marked overexpression in a
subset of cases [10-12]. The outlier-sum statistic explic-
itly identifies genes with extremely high or low expression
values in a subset of the samples.
In this paper we present statistical methods for identi-
fying prognostic genes whose expression values are
clearly separated into two groups. Our approach is unsu-
pervised in the sense that we first screen for genes with
bimodal gene expression distributions and then evaluate
their prognostic power. The resulting gene lists contain
promising candidates for prognostic or predictive signa-
tures. The clear separation into two groups makes the
classification of future samples more reliable.
We first describe all measures and tests for the detec-
tion of bimodal distributions. Then we apply these mea-
sures to a microarray data set consisting of 194 breast
cancer patients with corresponding whole genome RNA
e x p r e s s i o n  da t a.  F o r  ea c h  m eas u r e ,  w e  o b t a i n  a  l is t  o f
ranked genes. We evaluate the prognostic power of all
genes with respect to disease-free survival using the
logrank test for survival data. We discuss the results from
two perspectives. First, we present a global assessment of
the ability of the measures to identify prognostic genes.
In an enrichment type analysis we quantify if significantly
many genes with prognostic power are ranked high
according to the bimodality measures. Second, we ana-
lyze the top-ranked genes in detail from a biological view-
point, identifying concrete interesting new candidates.
Methods
We first briefly present the k-means algorithm as a stan-
dard algorithm for clustering numerical values into two
groups. We also describe a model-based clustering
approach. Then we introduce different measures for
assessing if the shape of a distribution supports the
assumption that two clear subgroups can be identified. In
other words, we present measures for testing bimodality
of distributions. We briefly describe the logrank test for
quantifying the statistical significance of survival time
differences between two groups of patients, and we pres-
ent the Kolmogorov-Smirnov test for the enrichment anal-
ysis comparing the prognostic genes with the genes with
bimodal distributions.
Cluster Algorithms
K-means
A straightforward method to assign patients to two
groups based on their gene expression values is to use a
clustering algorithm. One popular method is the k-means
algorithm.Hellwig et al. BMC Bioinformatics 2010, 11:276
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In the univariate case, let x1,..., xn be a set of observa-
tions. Given k  <n initial distinct cluster centers the k-
means algorithm partitions the set into k groups by mini-
mizing the Within Cluster Sum of Squares
, where Cj, j = 1,..., k, is the
jth cluster, nj is the number of elements in cluster Cj and
 is the cluster center. The algorithm is
an iterative process that alternates between assigning
data points to clusters based on their distances to cluster
prototypes and updating the prototypes based on new
cluster assignments.
K-means is sensitive to the initially randomly selected
cluster centers [13]. As we want to discriminate a group
w i t h  l o w  e x p r e s s i o n  v a l u e s  f r o m  a  g r o u p  w i t h  h i g h
expression values we choose for each gene its minimum
and its maximum observed expression value as initial
centers.
Model-based clustering
The assumption for this approach is that the distribution
Y of a gene with bimodal expression can be expressed as a
mixture of two gaussian distributions Y1  and  Y2  with
parameters μ1,   and  μ2, ,  respectively.
where Δ ∈ {0, 1} with P(Δ = 1) = π. π is the probability
of belonging to Y1. Let ϕθ denote the normal density with
parameters θ = (μ, σ2). Then the density of Y is given by
The parameters of the mixture model are determined
using the EM-algorithm.
To fit the models to our data we make use of the R
package mclust[14,15]. Typically equality of variances is
not assumed and we fit models with unequal variances.
However, in cases with only one outlier in the expression
distribution a model with unequal variances is not suit-
able since one component has variance 0. In this case we
fit a two component model with equal variances.
Tests for bimodality
The first two scores for testing bimodality quantify
whether the partitioning of the expression values into two
groups is adequate. We want to quantify whether assum-
ing two clusters is more appropriate than assuming one
cluster. The tests are based on the decomposition of the
Total Sum of Squares   as
where BSS is the Between Cluster Sum of Squares and
WSS the Within Cluster Sum of Squares.
Variance reduction score
The variance reduction score (VRS) is defined as the ratio
of WSS and TSS:
VRS measures the proportion of variance reduction
when splitting the data into two clusters. The value of this
score lies in the interval [0; 1], and a low score indicates
an informative split.
Weighted variance reduction score
The weighted variance reduction score (WVRS) measures
the variance reduction independent of the cluster sizes.
In the numerator we calculate the mean of the two within
cluster variances. The denominator is the sample vari-
ance as above for the VRS. We define
In this case the variance of a cluster with few observa-
tions has the same influence as the variance of a large
cluster. The value of this score can be larger than 1.
Again, a low score reflects bimodality. WVRS has the
ability to also identify splits into two clusters with
extremely unequal sample sizes.
Dip Test of Unimodality
The Dip Test of Unimodality was suggested by Hartigan
and Hartigan (1985) [7]. The dip statistic is defined as the
maximum difference between an empirical distribution
function and the unimodal distribution function that
minimizes that maximum difference.
For two arbitrary bounded functions F and G define
ρ(F, G):= supx|F(x)-G(x)|. Define 
for a class   of bounded functions. Let   denote the
class of unimodal distribution functions. Then the dip of
a distribution function F is defined by  .
To test the null hypothesis that F has a unimodal density
Hartigan and Hartigan proposed the statistic D(Fn),
where Fn is the empirical distribution function of a ran-
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dom sample of size n. The distribution of D(Fn) is com-
pared with the distribution of D(F), where F  is the
uniform distribution on [0; 1]. Hartigan and Hartigan [7]
showed that the dip is asymptotically larger for the uni-
form distribution than for any other unimodal distribu-
tion.
To calculate the dip statistic we make use of the R pack-
age diptest [16], which also provides a table of empir-
ical percentage points of the dip statistic D(Fn) for some
specified sample sizes n. This distribution can be used to
calculate p-values for the dip test, where the null hypoth-
esis is a unimodal distribution.
Kurtosis
Teschendorff et al. (2006) [8] proposed an approach to
identify genes with bimodal density based on model-
based clustering and kurtosis. The general approach is
based on two steps. To select the optimal number of clus-
ters and to find bimodal expression profiles a clustering
algorithm is used together with a model selection crite-
rion. Then the kurtosis can be used to rank the bimodal
genes according to if they define major subgroups or out-
lier subgroups. Kurtosis is related to the fourth central
moment and can be defined by
Given a gene's expression values x = (x1,..., xn) an unbi-
ased estimate for the kurtosis is given by
A gaussian distribution has kurtosis K  = 0, whereas
most non-gaussian distributions have either K > 0 or K <
0. Specifically, a mixture of two approximately equal mass
normal distributions must have negative kurtosis since
the two modes on either side of the center of mass effec-
tively flatten out the distribution. A mixture of two nor-
mal distributions with highly unequal mass must have
positive kurtosis since the smaller distribution lengthens
the tail of the more dominant normal distribution [8]. If
there is an 80%-20% split of the samples into two groups,
then the kurtosis is close to 0 [9]. Therefore biologically
interesting genes might be missed.
We calculate the kurtosis for all genes without a prior
feature selection step.
Likelihood Ratio
Using the likelihood ratio of a normal model and a mix-
ture normal model to identify bimodal distributions was
suggested by Ertel and Tozeren (2008) [6]. We fit a nor-
mal model and a mixture normal model to the expression
values for each gene using the mclust package and cal-
culate the likelihood ratio
where L1 is the likelihood of the normal model with one
component and L2 is the likelihood of a normal mixture
model with two components with unequal variance.
Small ratios indicate that the distribution is unimodal,
whereas large ratios suggest that the expression values are
bimodally distributed.
Bimodality Index
The Bimodality Index introduced by Wang et al. (2009)
[9] is a criterion to identify and rank bimodal signatures
from gene expression data. It is assumed that the distri-
bution of a gene with bimodal expression can be
expressed as a mixture of two normal distributions with
means  μ1 and  μ2 and equal standard deviation σ. The
standardized distance δ between the two populations is
given by
For identifying genes with bimodal distribution the null
hypothesis is δ  = 0. Then the bimodality index (BI) is
defined by
where π is the proportion of observations in the first
component.
For a given data set δ and π can be estimated using
mclust. Then BI can be calculated using the estimated
values. Larger values of BI correspond to bimodal distri-
butions where the two components are easier to distin-
guish. Wang et al. recommend BI = 1.1 as a cutoff to
select bimodally distributed genes.
Outlier-Sum Statistic
Another approach to group genes by expression values is
based on the calculation of outlier sums as proposed by
Tibshirani and Hastie (2007) [12]. This method is able to
detect genes with unusually high or low expression in
some but not all samples. Tibshirani and Hastie assume
that the samples fall into a reference and a disease group.
However, as we only consider tumor samples we modified
the method for our purpose.
Let medi and madi be the median and the median abso-
lute deviation of the expression values of gene i. First, the
expression values xij of each gene are standardized as fol-
lows:
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Let  qr(i) be the rth percentile of the   values and
IQR(i) = q75(i) - q25(i) the interquartile range. All values
smaller than IQR(i) - q25(i) or greater than IQR(i) + q75(i)
are defined to be outliers. The outlier-sum statistic for
positive outliers is defined as
Wi is large if there are many outliers in the data or few
extreme outliers with high values, and Wi is zero if there
are no outliers. Analogously the outlier-statistic for nega-
tive outliers is defined as
The outlier-sum statistic is the maximum of Wi and W'i
in absolute value.
For the survival analysis we need to split patients into
two groups. We consider the outliers that are used to cal-
culate the outlier sum as one group and all other observa-
tions as the other group.
Testing for prognostic relevance
For each gene we compare the hazard rates of two patient
subgroups obtained by the different methods. The goal is
to determine whether the survival in the two groups dif-
fers. We test the hypothesis H0: h1(t) = h2(t), for all t ≤ τ,
against the alternative that the hazard rates differ for
some t ≤ τ. τ is the largest time at which both groups have
at least one subject at risk. We make use of the logrank
test which is a nonparametric test for right-censored data
first proposed by Mantel (1966) [17].
Let  t1 <t2 < ... <tD be the distinct death times in the
pooled sample. Then dij is the number of events in the jth
sample out of Yij individuals at risk at time ti, j = 1, 2, i =
1,..., D. Let di = di1 + di2 and Yi = Yi1 + Yi2 be the number of
events and the number at risk in the combined sample at
time ti. The test statistic Z of the logrank test is given by
When the null hypothesis is true and the sample sizes
in the two groups are similar, asymptotically Z has a stan-
dard normal distribution. In the case of highly unequal
sample sizes, especially if one group contains less than
five patients, the asymptotic distribution under the null
hypothesis is not appropriate anymore [18,19]. Thus we
do not make use of the normal distribution for obtaining
significance values. Instead, we use a permutation test.
We calculate the test statistic for 100.000 random permu-
tations of the patients and determine the percentage of
values more extreme than the observed value of the test
statistic. Using k-means we always get two groups of
patients. However, using the model-based clustering
approach and the outlier sum approach it is possible that
for some genes all patients are in the same group so that
the logrank test can not be applied. As these genes rather
have unimodal expression profiles we decided to set the
corresponding p-value 1.
Adjustment for multiple testing
We use the logrank test described in the previous Section
to test for prognostic relevance for each of the genes.
Here, we have to take the multiple testing problem into
account. The significance level α of a hypothesis test con-
trols the Type I error, i.e. the probability of rejecting a
true null hypothesis. If m independent true hypotheses
are tested simultaneously one would expect m · α p-val-
ues p <α. Therefore one has to adjust for multiple testing.
There are different correction methods. The Bonfer-
roni-Holm method [20] controls the Familywise Error
Rate (FWER), i.e. the probability of rejecting at least one
true null hypothesis.
The method suggested by Benjamini and Hochberg
(1995) [21] controls the False Discovery Rate (FDR),
which is the expected proportion of falsely rejected
hypotheses among all rejected hypotheses. This proce-
dure is less conservative than the Bonferroni-Holm
method and often more appropriate for high-dimensional
microarray data.
Let  p(1), . . ., p(m) denote the ordered p-values of m
hypothesis tests, i.e. p(i) ≤ p(i+1). Then the adjusted p-val-
ues, also referred to as q-values, can be calculated itera-
tively as follows
where q(m) = p(m).
Analyzing gene lists for enrichment with prognostic genes
To determine whether there is an enrichment of the top-
scoring bimodality genes with prognostic genes, we rank
the genes based on the different bimodality scores. We
then select the 250 genes with smallest p-values of the
logrank test. These genes differ for the different
approaches (i.e. k-means, model-based clustering, outlier
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sum). In this context, we call these genes prognostic
genes.
An enrichment of the top-scoring bimodality genes
with prognostic genes corresponds to small ranks of
prognostic genes in the ranked list. We test the null
hypothesis that the ranks of the prognostic genes are uni-
formly distributed among the bimodality-ranked genes
with a one-sample Kolmogorov-Smirnov test, which is a
nonparametric test of equality with a given one-dimen-
sional reference function. The Kolmogorov-Smirnov sta-
tistic quantifies a distance between the empirical
distribution function of the sample and the cumulative
distribution function of the reference distribution.
We perform the one-sided Kolmogorov-Smirnov test
for testing the hypothesis that the cumulative distribution
function of the ranks of the prognostic genes is not
greater than the distribution function of a uniform distri-
bution. Let Fn denote the empirical distribution function
of the sample and F the distribution function of the refer-
ence distribution, then the test statistic is given by
The null distribution of this statistic is calculated under
the null hypothesis that the sample is drawn from the ref-
erence distribution. If F is continuous the distribution of
 does not depend on F but just on the sample size n.
For n > 40 approximative p-values can be derived from
the asymptotical distribution of  [22].
Patients and gene array analysis
The Mainz study cohort consists of 194 node-negative
breast cancer patients who were treated at the Depart-
ment of Obstetrics and Gynecology of the Johannes
Gutenberg University Mainz between the years 1988 and
1998 [1]. All patients underwent surgery and did not
receive any systemic therapy in the adjuvant setting.
Gene expression profiling of the patients' RNA was per-
formed using the Affymetrix HG-U133A array, contain-
ing 22283 probe sets, and the GeneChip System [23]. The
normalization of the raw data was done using RMA [24]
from the Bioconductor [25] package affy[26]. The raw
.cel files are deposited at the NCBI GEO data repository
[27] with accession number GSE11121.
Results
We analyze and compare distributions of bimodality
measures. All methods presented in the methodology
section are applied to the Mainz cohort study. For all
bimodality measures we present the top-scoring genes
and we analyze their ability to detect prognostic genes.
We discuss and interpret commonalities and differences
in the conclusions section.
Correlation between bimodality scores
We calculated the seven scores for quantifying bimodality
for all 22283 genes measured in the Mainz study. First, we
analyze the global correlations between the measures.
The results show that indeed a clear group structure
exists which enables a classification of the measures for
our application.
We point out that only the dip score is directly con-
nected to a significance value since it is based on a test
statistic with corresponding null distribution. The null
distribution provides p-values for rejecting the hypothe-
sis of unimodality. The empirical percentage point for
sample size n = 200 and test level α = 0.05 is 0.037. For 8
genes the dip statistic is larger than 0.037 such that the
null hypothesis of a unimodal density can be rejected. For
the other bimodality scores no direct significance calcula-
tion resulting in p-values is available. For the bimodality
index Wang et al. recommend the cutoff 1.1 which is
exceeded by 1596 genes. In Table 1 and 2 we present the
pairwise Pearson and Spearman correlation for the seven
scores applied to all genes. Both methods show similar
results. Here, the likelihood ratio is transformed to the
logarithmic scale, which increases the Pearson correla-
tion to other scores considerably due to the removal of
outlier effects. Considerable correlation can be observed
for various pairs of scores. The log-likelihood ratio and
the outlier sum have the largest correlation (0.863). The
Dx F x n
x
n
+ =− sup[F( ) ( )]. (16)
Dn
+
nDn
+
Table 1: Pearson correlation of the bimodality scores
VRS WVRS dip kurtosis BI log(LR) OS
VRS 1.000 0.314 -0.079 0.172 -0.491 -0.173 -0.118
WVRS 0.314 1.000 -0.054 0.544 -0.062 0.548 0.398
dip -0.079 -0.054 1.000 -0.039 0.013 -0.049 -0.109
kurtosis 0.172 0.544 -0.039 1.000 -0.174 0.661 0.407
BI -0.491 -0.062 0.013 -0.174 1.000 0.244 0.334
log(LR) -0.173 0.548 -0.049 0.661 0.244 1.000 0.863
OS -0.118 0.398 -0.109 0.407 0.334 0.863 1.000Hellwig et al. BMC Bioinformatics 2010, 11:276
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only other correlations larger than 0.5 are observed pair-
wise between log-likelihood ratio, WVRS, and kurtosis.
In Table 2 we present the same analysis replacing the
Pearson correlation with the Spearman rank correlation.
The correlation coefficient of WVRS and kurtosis is now
the largest (0.865), and the measures log-likelihood ratio,
WVRS, kurtosis, and outlier sum all have pairwise high
rank correlations.
Figure 1 shows dendrograms generated using 1-C  as
distance matrix, where C is the correlation matrix of the
seven scores. Both figures clearly show two groups. On
the one side of the dendrogram there are the dip statistic,
the bimodality index and -(kurtosis), i.e. the kurtosis
score starting with largest values. Overall there is no large
Pearson correlation between these scores, the distance is
in most cases close to 1. The other group contains the
highly correlated measures log-likelihood ratio, WVRS,
kurtosis, and the outlier-sum statistic, as well as VRS
which has a large distance to the other scores.
In summary, the outlier-sum statistic and the log-likeli-
hood ratio have the highest correlation (Pearson 0.863
and Spearman 0.786). In both dendrograms these scores
are thus very close. WVRS and kurtosis also belong to
this group, whereas VRS, dip statistic, and bimodality
index seem to measure different distributional features,
at least according to the overall correlation.
Figure 2 shows smoothed scatterplots for the compari-
son of selected scores. The strong positive correlation
between the log-likelihood ratio and the outlier-sum sta-
tistic is clearly visible (Figure 2(a)). The areas of highest
local density are at low values for the both scores. The
correlation between the log-likelihood ratio and the kur-
tosis is smaller, but still obvious. However, at higher val-
ues of these scores there is a large dispersion; there are
some genes with small log-likelihood ratio but very large
positive kurtosis (Figure 2(b)). WVRS and the kurtosis
are also positively correlated. Some of the genes with
largest positive kurtosis have medium WVRS. The high-
est local density is at WVRS values between 0 and 1.
Distributional shapes of genes with extreme bimodality 
scores
In order to obtain an impression of types of distributions
detected by the different bimodality scores we present
histograms of the expression values for the top 6 genes
identified by each score, respectively (Figure 3, Figure 4,
Figure 5). The most striking differences can be observed
between the shapes detected by the correlated measures
log-likelihood ratio, WVRS, kurtosis and outlier-sum sta-
tistic on the one side and all other scores on the other
side. The former scores all identify genes with a main uni-
modal expression distribution and few additional outli-
ers. The other scores detect mainly genes whose
expression values can be grouped into two separated
groups.
This difference can be exemplified with the clustering
approaches resulting in the VRS and WVRS scores. The
histograms for the top genes of VRS all indicate a large
group and a smaller group (cf. Figure 3(a)). Except for
FOXA1, the smaller group has larger expression values.
On the other hand, the expression values of the top genes
according to WVRS show a unimodal density with one or
two outliers. Typically, most expression values of these
genes are low, often in a range that could be regarded as
noise, whereas the outliers have high expression values.
This different behavior between VRS and WVRS is due to
the larger impact of a subset with few samples when using
WVRS, since then the variance reduction is calculated by
averaging the variances of the two resulting subsets.
Similarly, the density of the genes with the largest posi-
tive kurtosis is unimodal with a small outlier group with
high expression values (cf. Figure 4(a)), whereas the top 6
genes according to negative kurtosis show bimodal densi-
t i e s  w i t h  a l m o s t  e q u a l  s i z e  g r o u p s  o r  a  f l a t  d e n s i t y
(SCGB1D2). For the top genes according to the likelihood
ratio one can see a large group and an outlier group with
large variance. Also the outlier-sum statistic detects
genes with densities with heavy tails in the higher intensi-
ties. For the dip statistic the top genes have clearly visible
bimodal densities (Figure 3(c)). The genes with the largest
Table 2: Spearman correlation of the bimodality scores
VRS WVRS dip kurtosis BI log(LR) OS
VRS 1.000 0.683 -0.086 0.613 -0.464 0.226 0.363
WVRS 0.683 1.000 -0.125 0.865 -0.008 0.681 0.752
dip -0.086 -0.125 1.000 -0.077 -0.009 -0.070 -0.144
kurtosis 0.613 0.865 -0.077 1.000 -0.100 0.736 0.692
BI -0.464 -0.008 -0.009 -0.100 1.000 0.437 0.311
LR 0.226 0.681 -0.070 0.736 0.437 1.000 0.786
OS 0.363 0.752 -0.144 0.692 0.311 0.786 1.000Hellwig et al. BMC Bioinformatics 2010, 11:276
http://www.biomedcentral.com/1471-2105/11/276
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Figure 1 Dendrograms of the correlation between the scores. 1-correlation matrix of the scores was used as distance matrix for average linkage 
hierarchical clustering.
d
i
p
−
(
k
u
r
t
o
s
i
s
)
B
I
V
R
S
l
o
g
(
L
R
)
O
S
W
V
R
S
k
u
r
t
o
s
i
s
0
.
0
0
.
5
1
.
0
1
.
5
2
.
0
(a) Dendrogram Pearson correlation
scores
H
e
i
g
h
t
V
R
S
W
V
R
S
k
u
r
t
o
s
i
s
l
o
g
(
L
R
)
O
S
d
i
p
−
(
k
u
r
t
o
s
i
s
)
B
I
0
.
0
0
.
5
1
.
0
1
.
5
2
.
0
(b) Dendrogram Spearman correlation
scores
H
e
i
g
h
t
Figure 2 Comparison of selected bimodality scores. Pairwise comparisons of selected bimodality scores. Smoothed density representations of the 
scatterplots, obtained through kernel density estimation. The higher the local density is, the darker are the areas. The points represent the first 500 
observations in the areas of lowest regional density. These observations can be regarded as potential outliers.
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bimodality index show bimodal densities, where the two
groups can have unequal sizes (Figure 5(a)). There is not
much overlap between the top six genes of all scores,
except for the gene HLA-DQA1 with a clear bimodal his-
togram. The gene is among the top list for the scores
detecting bimodal shapes, i.e. VRS, dip, negative kurtosis,
and bimodality index, and additionally for WVRS.
In conclusion, all considered scores are applicable for
the identification of genes with characteristic distribu-
tions. However, the distribution curves differ particularly
with respect to the number of patients (samples) consti-
tuting the high expression group.
Prognostic relevance of genes with extreme bimodality 
scores
For the top genes presented in the previous section, we
plot in Figure 6, Figure 7 and Figure 8 Kaplan-Meier
curves for the top-scoring genes and corresponding p-
values of the logrank test when discriminating patients
according to low or high expression values. As described
in the methodology section we use different methods to
assign patients to a low and a high expression group. For
VRS and WVRS we use the k-means algorithm, for the
kurtosis based approach, the likelihood ratio, and the
bimodality index we use the results of the model-based
clustering, and for the outlier-sum statistic we use the
main group and the outlier group. We argue that the k-
means approach is also appropriate for the results of the
dip test as we see that the k-means algorithm is able to
separate the groups adequately at least for the top ranked
genes.
For three of the top genes detected by VRS the survival
in the two groups differs considerably. For MAGEA2 and
ZIC1, the survival prediction is worse for the group with
high expression values, for FOXA1 for the group with low
expression values. The only patient in the high value
group for UGT1A@ and CTNNA2 drops out at an early
point, resulting in a small p-value (p = 0.057, see Figure
6(b)). This patient is the same for both genes. Among the
top 6 genes for the dip statistic there are two with p-val-
ues smaller than 0.05, namely TFAP2B and ERAP2. For
both genes the survival in the group with lower expres-
sion values is worse. For two of the 6 genes with largest
positive kurtosis, UGT1A@ and MYH7, the survival in
the patient subgroups differs significantly. Patients with
high expression values have worse prognosis (Figure
7(a)). Among the top 6 genes for negative kurtosis, there
is just one (TFAB2B) that splits the samples in two groups
Figure 3 Histograms of the top 6 genes for WVRS, VRS and dip.
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Figure 4 Histograms of the top 6 genes for positive and negative Kurtosis and the likelihood ratio.
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Figure 5 Histograms of the top 6 genes for the bimodality index and the outlier sum.
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with significantly different prognosis. MAGEA2 and
MAGEA6 are the two genes identified as bimodal by the
likelihood ratio score whose p-values of the logrank test
are small. Here, the p-value for MAGEA2 is highly signif-
icant (p < 0.001). Among the 6 top-scoring genes based
on the bimodality index the two genes FOXA1 and ZIC1
lead to a prognostic split. Among the top 6 genes accord-
ing to the outlier-sum statistic only VGLL1 generates a p-
value smaller than 0.05.
Prognostic relevance of bimodality scores on a genome-
wide scale
In a next step we systematically analyzed the overlap
between two different gene sets, namely genes identified
by a score and genes associated with prognosis. The goal
is to find out if among the bimodal genes identified by the
different scores genes associated with prognosis are over-
represented. Table 3 shows the top 10 genes for each of
the scores with corresponding p-values of the logrank test
and the associated q-values.
For the genome-wide evaluation, we first sorted the
genes based on the bimodality scores. For VRS and
WVRS we generated gene lists with smallest scores at the
top. For the dip statistic, the bimodality index, the likeli-
hood ratio and the outlier-sum statistic we generated
decreasing lists. For the kurtosis we look at both the
increasing as well as the decreasing list. We then selected
the 250 genes with smallest p-values for survival differ-
ences. These gene lists are different for the different
approaches.
The results of Fisher tests and Kolmogorov-Smirnov
tests for the scores are displayed in Table 4. Plots corre-
sponding to a Kolmogorov-Smirnov type test are shown
i n  A d d i t i o n a l  f i l e  1 :  S u p p l e m e n t a l  F i g u r e  1 .  F o r  V R S ,
among the top 200 genes there is just one of the 250 prog-
nostic genes, but among the top 1000 genes there are 16.
This number is significantly larger than expected under
the null hypothesis of independence between bimodality
score and prognostic relevance (p = 0.01). The Kolmogo-
rov-Smirnov test rejects the null hypothesis that the
ranks of the prognostic genes are uniformly distributed (p
< 10-7). Thus there is a clear enrichment with prognostic
genes in the top-scoring genes.
For WVRS, among the 1000 top-scoring genes there are
just 13 of the 250 prognostic genes (p = 0.333). Appar-
ently there is no enrichment with prognostic genes on top
Figure 6 Kaplan-Meier curves for top 6 genes for WVRS, VRS and dip. Kaplan-Meier curves for the top 6 detected genes for WVRS, VRS and dip. 
In every graphic the green line denotes the survival in the group with lower expression values for the corresponding gene and the blue line the sur-
vival in the group with higher expression values. The graphics also contain the corresponding p-values of the logrank test.
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(b) WVRS
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(c) dip
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of the list and the global Kolmogorov-Smirnov test can
not reject (p = 0.547). However, many of the prognostic
genes have large WVRS values (see Additional file 1).
These genes have expression distributions with a main
unimodal distribution and an additional outlier group
with large variance. For the list based on the dip statistic
just two of the prognostic genes are among the top 200
and 9 among the top 1000 genes. Here, the null hypothe-
sis of the Kolmogorov-Smirnov test can not be rejected (p
= 0.749).
Among the first 1000 genes on the list with decreasing
kurtosis values there are 17 highly prognostic genes (p =
0.059), whereas on the increasing list there are 8 genes (p
= 0.878). The result of the Kolmogorov-Smirnov test for
the decreasing kurtosis list is borderline significant (p =
0.003). The prognostic genes are overrepresented among
the first half of the ranked gene list (see Additional file 1).
For the likelihood ratio the ranks of the prognostic genes
are significantly not uniformly distributed (p < 10-12), and
among the top 1000 genes we find 21 prognostic genes (p
= 0.005). For the bimodality index the global enrichment
is also highly significant (p < 10-12). There is a significant
enrichment for the top-ranked genes. 22 of the 250 prog-
nostic genes are among the first 1000 genes according to
the bimodality index (p = 0.002).
Lastly, for the outlier-sum statistic a highly significant
overrepresentation of the prognostic genes among the
top-scored genes can be observed (p < 10-12). Among the
first 1000 genes are 26 highly prognostic genes (p < 10-4).
This shows that on a global level the likelihood ratio,
the bimodality index and the outlier-sum statistic work
best for the identification of prognostic genes with
bimodal density, many prognostic genes have densities
with heavy tails. The clustering based approaches VRS is
better suited to detect prognostic genes than the dip sta-
tistic.
It is important to note that we found that the threshold
250 for determining the prognostic genes is not critical.
We tried various other cutoffs. Using 50 prognostic
genes, no significant results are obtained. In the range
from 100 to 1000 genes we found that the results for VRS,
bimodality index, likelihood ratio and the outlier-sum
statistic are similar.
Figure 7 Kaplan-Meier curves for the top 6 genes for positive and negative Kurtosis and the likelihood ratio. Kaplan-Meier curves for the top 
6 detected genes for positive and negative Kurtosis and the likelihood ratio. In every graphic the green line denotes the survival in the group with 
lower expression values for the corresponding gene and the blue line the survival in the group with higher expression values. The graphics also con-
tain the corresponding p-values of the logrank test.
0 5 10 15 20
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
 UGT1A@
years
p= 0.0135
p
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
a
l
i
v
e
(a) positive kurtosis
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(b) negative kurtosis
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(c) Likelihood Ratio
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Validation on other data sets
To validate our results we repeated our analysis on an
other free available data set. The raw .cel files and clinical
parameters of the Rotterdam cohort [28,29] were down-
loaded from the NCBI GEO data repository with acces-
sion number GSE2034 (n = 286). Here, the outlier-sum
statistic and the likelihood ratio also have the smallest p-
values of the logrank test (see Additional file 2: Supple-
mental Figure 2). For the bimodality index there is also a
significant enrichment (p = 0.01). However, we do not
observe a significant overrepresentation of the prognostic
genes among the top-scoring genes according to VRS. For
the gene list based on decreasing kurtosis the we also find
a significant enrichment (p < 10-7).
To determine whether our results also hold for known
prognostic subgroups we used a pooled cohort of 766
patients from different free available data sets: GSE11121
(n = 200), GSE2034 (n = 286), GSE7390 (n = 177) [30] and
GSE6532 (n = 103) [31,32]. We look at three subgroups
defined by the expression of the two genes ESR1 and
erbB2, namely ESR1+/erbB2- (n = 519), erbB2+ (n = 107)
and ESR1-/erbB2- (n = 140). In this analysis the variable
for assessing prognostic power of the genes is the distant
metastasis free interval (MFI).
In the ESR1+/erbB2- subgroup of the pooled cohort the
bimodality index has the smallest p-value of the logrank
test (p < 10-14, see Additional file 3: Supplemental Figure
3). A significant enrichment of the top scoring genes with
prognostic genes can also be observed for the likelihood
ratio (p < 10-8) and for the outlier-sum statistic (p < 10-5).
For the kurtosis score the prognostic genes have mainly
negative values. There are also many genes with large
positive kurtosis but these are not the top genes for posi-
tive kurtosis. For VRS the result of the Kolmogorov-
Smirnov test is borderline significant (p = 0.018).
In the erbB2+ subgroup of the pooled cohort the Kolm-
ogorov-Smirnov test significantly rejects the null hypoth-
e s i s  f o r  v a r i o u s  m e a s u r e s  ( s e e  A d d i t i o n a l  f i l e  4 :
Supplemental Figure 4). Some of the prognostic genes are
at the top of the ranked gene lists based on VRS, WVRS,
increasing kurtosis, the bimodality index and the likeli-
hood ratio. The smallest p-value can be observed for the
negative kurtosis (p < 10-9). Here, for the outlier-sum sta-
tistic no significant result is obtained (p = 0.625). In the
ESR1-/erbB2- subgroup the only considerable enrich-
ment can be observed for negative kurtosis (p < 10-4, see
Additional file 5: Supplemental Figure 5).
It is important to note that the pooling of data sets can
be problematical since in some cases bimodal expression
distributions are an artifact of the pooling of experiments
(see Additional file 6: Supplemental Figure 6).
Analysis of established genes with bimodal distribution
Techniques for the identification of bimodally expressed
genes should be able to identify genes, whose bimodal
distribution is already known. The best established genes
Figure 8 Kaplan-Meier curves for the top 6 genes for the bimodality index and the outlier sum. Kaplan-Meier curves for the top 6 detected 
genes for the bimodality index and the outlier sum. In every graphic the green line denotes the survival in the group with lower expression values for 
the corresponding gene and the blue line the survival in the group with higher expression values. The graphics also contain the corresponding p-
values of the logrank test.
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(a) Bimodality Index
0 5 10 15 20
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
 FOXA1
years
p= 0.0268
0 5 10 15 20
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
 HLA−DQA1
years
p= 0.748
0 5 10 15 20
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
 ZIC1
years
p= 0.0229
0 5 10 15 20
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
 CRISP3
years
p= 0.974
0 5 10 15 20
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
 TDRD12
years
p= 0.0792
0 5 10 15 20
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
 FABP7
years
p= 0.486
p
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
a
l
i
v
e
(b) Outlier−Sum Statistic
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Table 3: Top 10 genes for the bimodality scores
VRS WVRS dip
gene p q gene p q gene p q
PSPHL 0.147 0.483 ST18 0.360 0.703 HLA-DQB1 0.140 0.473
MAGEA2 0.012 0.158 UGT1A@ 0.056 0.311 HLA-DQA1 0.748 0.914
HLA-DQA1 0.748 0.914 CTNNA2 0.056 0.311 TFAP2B 0.024 0.216
FOXA1 0.027 0.225 HLA-DQA1 0.748 0.914 HLA-DQA1 0.205 0.560
ZIC1 0.023 0.213 UTS2 0.621 0.860 ERAP2 0.034 0.251
CRISP3 0.974 0.993 CALCA 0.539 0.821 HLA-DRB4 0.929 0.981
PCSK1 0.053 0.304 SCG3 0.622 0.878 NLRP2 0.162 0.506
DSG1 < 10-3 0.033 TFAP2B 0.024 0.216 IQGAP1 0.089 0.385
MAGEA4 < 10-3 0.028 MYH7 0.072 0.345 SAT1 0.712 0.901
UGT2B4 0.835 0.950 HAPLN1 0.072 0.345 DSCC1 0.072 0.346
pos kurtosis neg kurtosis likelihood ratio
gene p q gene p q gene p q
UGT1A@ 0.013 0.137 HLA-DQA1 0.764 0.913 PCSK1 0.304 0.622
CTNNA2 0.833 0.941 TFAP2B 0.010 0.120 MAGEA6 0.068 0.298
UTS2 0.457 0.742 SCGB1D2 0.566 0.807 CHGB 0.488 0.764
CALCA 0.304 0.622 SLC1A1 0.200 0.514 ACE2 0.321 0.636
SCG3 0.494 0.768 PEG10 0.570 0.811 MAGEA2 <10-03 0.015
MYH7 0.010 0.120 HLA-DQA1 0.238 0.557 FGB 0.785 0.921
HAPLN1 0.733 0.897 PSD3 0.067 0.297 DSG1 0.024 0.181
FGA 0.417 0.713 unknown 0.022 0.172 MSLN 0.138 0.423
HTR2C 0.016 0.148 ERAP2 0.303 0.622 UGT2B4 0.112 0.382
GLUD2 0.986 0.995 HLA-DQB1 0.243 0.561 CARTPT 0.382 0.691
bimodality index outlier sum
gene p q gene p q
PSPHL 0.147 0.449 FABP7 0.486 0.783
FOXA1 0.027 0.189 S100A7 0.720 0.904
HLA-DQA1 0.748 0.909 FAM5C 0.853 0.954
ZIC1 0.023 0.175 CRISP3 0.667 0.884
CRISP3 0.974 0.990 GRIA2 0.662 0.882
TDRD12 0.079 0.332 VGLL1 0.034 0.224
TFAP2B 0.024 0.178 MAGEA6 0.055 0.287
MAGEA3 0.032 0.206 ALB 0.196 0.551
UGT8 0.023 0.175 ASCL1 0.530 0.811
S100A7 0.817 0.936 MAGEA3 0.151 0.489
For each of the scores the table contains the 10 top-scoring genes. Also the p-values obtained by the logrank test and the corresponding q-
values are given.Hellwig et al. BMC Bioinformatics 2010, 11:276
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with bimodal frequency distributions in breast cancer are
the estrogen receptor (ESR1) and erbB2 [1,2]. Histograms
of the expression profiles of these genes in our data set
are shown in Figure 9 and clearly indicate subgroups.
The ranks of these two genes based on the different
bimodality scores are presented in Table 5. For many
scores, the genes obtain small ranks. ESR1 is ranked by
the bimodality index and VRS at position 50 and 92,
respectively, and also has small ranks for WVRS, the out-
lier-sum statistic, and the likelihood ratio. Only for the
dip statistic and for the kurtosis ESR1 obtains medium
ranks.
ErbB2 also has the smallest rank when using the bimo-
dality index (338) and has small ranks for VRS, the out-
lier-sum statistic, and the likelihood ratio. The only
extreme difference can be observed for WVRS, where
erbB2 has rank 21505. The large value of WVRS is due to
the large variance in the smaller group. Dip finds groups
with almost equal sizes and thus fails to identify the
groups with unequal sizes generated by ESR1 and erbB2
in our data set.
Discussion and Conclusion
Genome-wide identification of genes with bimodal
expression distributions is relevant since distinguishabil-
ity of high and low expression groups is easier compared
to genes with unimodal gene expression distributions. In
addition, such methods may be helpful for the identifica-
tion of candidate genes that are targets of somatic or
germ-line mutations.
In the present study, we compared seven scores for the
genome-wide identification of bimodal genes. Interest-
ingly, the expression distributions of genes identified by
the different scores showed characteristic differences. In
general, two different concepts can be distinguished,
namely the splitting of observations into two separated
groups and the identification of a mixture of a reference
group and outlier observations. The splitting approaches
are the following: The dip test is a nonparametric test of
unimodality. In our context, it identifies genes with
approximately similar sizes of low and high expression
groups. Genes with negative kurtosis values also show
bimodal densities with almost equal mass of the groups
or with flat distributions. The top genes according to the
bimodality index mostly have bimodal distributions with
unequal group sizes.
The outlier approaches are the correlated measures log-
likelihood ratio, WVRS, kurtosis, and the outlier-sum sta-
tistic. Genes with large positive kurtosis have densities
with a large group and a small group containing only a
few patients. The likelihood ratio and the outlier-sum sta-
tistic both find genes with heavy tails in their expression
profiles. In our evaluation, usually the smaller group
showed higher expression values.
The clustering-based approach VRS seems to be a com-
promise, see Figure 3(a). Both genes identified by the
splitting methods and by the outlier methods are ranked
top. VRS is also suitable for detecting splits with corre-
sponding noticeable different group sizes.
The second result of our analysis is which measures are
best suited for finding prognostic genes. Genome-wide
analysis of all genes in the Mainz cohort study demon-
strates that the prognostic genes are clearly overrepre-
sented among the genes identified by various measures.
The smallest p-values of the Kolmogorov-Smirnov test
that evaluates the entire bimodality ranking at once were
obtained for the likelihood ratio, the outlier-sum statistic
and the bimodality index. The outlier-sum approach pro-
duces a gene list in which prognostic genes have small
ranks (p < 10-12). There is a strong Pearson correlation
between the log-likelihood ratio and the outlier-sum sta-
tistic (0.863) and the p-value of the Kolmogorov-Smirnov
test for the likelihood ratio is also very small (p < 10-12).
Both methods identify similar types of distributions.
Many of the prognostic genes have densities with heavy
tails. The bimodality index finds genes with bimodal den-
Table 4: Results of enrichment tests
Fisher test KS test
score 200 genes p-value 1000 genes p-value p-value
VRS 1 0.896 16 0.099 < 10-07
WVRS 4 0.188 13 0.333 0.547
dip 2 0.659 9 0.795 0.749
pos kurtosis 2 0.659 17 0.059 0.003
n e g  k u r t o s i s 20 . 6 5 9 80 . 8 7 80 . 9 8 8
LR 1 0.896 21 0.005 < 10-12
BI 0 1.000 22 0.002 < 10-12
outlier sum 0 1.000 26 < 10-04 < 10-12Hellwig et al. BMC Bioinformatics 2010, 11:276
http://www.biomedcentral.com/1471-2105/11/276
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sities where the group sizes can be unequal. The prognos-
tic genes are clearly overrepresented among the top-
scoring genes according to the bimodality index (p < 10-
12). The next best measure is VRS (Table 4). This means
that both splitting methods (like the bimodality index)
and outlier methods (like the likelihood ratio) can be use-
ful for finding interesting prognostic genes. For the
weighted cluster score WVRS, the overall overrepresen-
tation of the prognostic genes among the top-scoring
genes is not significant (p = 0.547). However, many of the
genes with large WVRS values obtain very small p-values
according to the logrank test. The expression profiles of
these genes show a unimodal distribution and a smaller
group with large variance. The validation of our results
using the Rotterdam cohort showed that the prognostic
genes were also clearly overrepresented among the top-
genes according to the likelihood ratio and the outlier-
sum statistic.
Another insight is that, in concordance with previous
findings, only small groups of patients who strongly over-
express certain prognostic factors show worse prognosis,
whereas dichotomization of the same factors at the
median results in no or a worse prognostic power [1].
Often, RNA expression levels in the high expression
groups are so high above those of the low expression
groups that the overlap is virtually zero. Therefore, out-
lier scores like the kurtosis may be particularly valuable
for screening for genes to be used subsequently in prog-
nostic signatures. For this type of genes, often, the num-
ber of patients in the high expression group is very small.
However, combination of several such bimodal genes may
nevertheless allow the identification of a high risk group
of an adequate size.
The dip is certainly not a technique of first choice for
preselecting genes for prognostic signatures. However,
dip may be ideal for the identification of genes whose
bimodal expression may be caused by genetic polymor-
phisms with frequent alleles which is of interest in drug
metabolism and other fields of toxicological research [33-
35].
Among the identified genes several have not yet been
recognized to be prognostic and bimodally expressed in
breast cancer. An extensive overview over the top identi-
fied genes in our study regarding their gene function and
the role of polymorphisms in tumor development is pre-
sented in Additional file 7: Supplemental Table 1. Impor-
tant examples are the genes MAGEA2 and MAGEA4 that
play central roles in immune response. Both have not yet
been reported to be prognostic in breast cancer nor to
show bimodal distributions. Further examples are des-
moglein 1 (DSG1) which is involved in intercellular junc-
tion of epithelial cells, the phase II metabolizing enzyme
UGT1A@, the cadherin-binding protein CTNNA2, and
myosin heavy chain 7 (MYH7), which so far has been
associated with heart disease but not with cancer. Exam-
ples where the polymorphism or its prognostic relevance
have already been reported are the transcription factor
FOXA1 and HAPLN1. FOXA1 has already been shown to
be a predictor of good outcome in breast cancer, in agree-
ment with the result of the present study. HAPLN1 con-
veys tumorigenic properties when overexpressed in
mesothelioma cells, but SNPs of the HAPLN1 locus were
not found to be associated with response to interferon
beta and a prognostic role in breast cancer has not been
reported yet (for details and references see Additional file
7).
In summary, we have established efficient techniques
for the genome-wide identification of genes with bimodal
expression distributions and we have analyzed their abil-
ity to generate patient splits with prognostic relevance.
Future research includes the analysis of multivariate
bimodality measures and the construction of prognostic
signatures by combining several genes with bimodal
expression distributions.
Figure 9 Histograms of ESR1 and erbB2 expression values.
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Table 5: Ranks of known bimodal genes
score ESR1 erbB2
VRS 92 808
WVRS 204 21505
dip 9055 15987
-(kurtosis) 11595 1023
likelihood ratio 623 426
bimodality index 50 338
outlier sum 296 480
The ranks of the known bimodal genes erbB2 and ESR1 based on 
the seven scores.Hellwig et al. BMC Bioinformatics 2010, 11:276
http://www.biomedcentral.com/1471-2105/11/276
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Availability
R code for measures of bimodality and linking them to
survival data is available at http://www.statistik.tu-dort-
mund.de/genetik-publikationen-bimodality.html.
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